Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to $93.3 million.

  • Editas Medicine's Shares Outstanding rose 1299.49% to $93.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $93.3 million, marking a year-over-year increase of 1299.49%. This contributed to the annual value of $82.7 million for FY2024, which is 118.32% up from last year.
  • According to the latest figures from Q3 2025, Editas Medicine's Shares Outstanding is $93.3 million, which was up 1299.49% from $87.4 million recorded in Q2 2025.
  • Editas Medicine's Shares Outstanding's 5-year high stood at $93.3 million during Q3 2025, with a 5-year trough of $67.5 million in Q1 2021.
  • Over the past 5 years, Editas Medicine's median Shares Outstanding value was $81.6 million (recorded in 2023), while the average stood at $76.6 million.
  • As far as peak fluctuations go, Editas Medicine's Shares Outstanding soared by 2311.98% in 2021, and later soared by 56.98% in 2023.
  • Editas Medicine's Shares Outstanding (Quarter) stood at $68.4 million in 2021, then increased by 0.6% to $68.8 million in 2022, then rose by 18.77% to $81.8 million in 2023, then rose by 1.18% to $82.7 million in 2024, then grew by 12.73% to $93.3 million in 2025.
  • Its Shares Outstanding was $93.3 million in Q3 2025, compared to $87.4 million in Q2 2025 and $83.7 million in Q1 2025.